Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).

Article  PubMed  Google Scholar 

Ricotti, A. et al. Incidence and prevalence analysis of non-small-cell and small-cell lung cancer using administrative data. Int. J. Env. Res. Public Health 18, 9076 (2021).

Article  CAS  Google Scholar 

Borghaei, H. et al. Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J. Clin. Oncol. 39, 723–733 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garassino, M. C. et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J. Clin. Oncol. 41, 1992–1998 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu, S. V. et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J. Clin. Oncol. 39, 619–630 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Novello, S. et al. Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J. Clin. Oncol. 41, 1999–2006 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng, B. et al. The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial. Signal. Transduct. Target. Ther. 9, 93 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meyer, M. L. et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet 404, 803–822 (2024).

Article  CAS  PubMed  Google Scholar 

Brahmer, J., Tykodi, S. S., Chow, L. Q., Hwu, W. J. & Topalian, S. L. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028 (2015).

Article  PubMed  Google Scholar 

Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255–265 (2017).

Article  PubMed  Google Scholar 

Chung, H. C. et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J. Thorac. Oncol. 15, 618–627 (2020).

Article  CAS  PubMed  Google Scholar 

Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393, 1819–1830 (2019).

Article  CAS  PubMed  Google Scholar 

Mazieres, J. et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann. Oncol. 30, 1321–1328 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Otano, I., Ucero, A. C., Zugazagoitia, J. & Paz-Ares, L. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. Nat. Rev. Clin. Oncol. 20, 143–159 (2023).

Article  PubMed  Google Scholar 

Schoenfeld, A. J. & Hellmann, M. D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37, 443–455 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu, S. V. et al. OA01.04 five-year survival in patients with ES-SCLC treated with atezolizumab in IMpower133: IMbrella a extension study results. J. Thorac. Oncol. 18, 2 (2023).

Google Scholar 

Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345–362 (2021).

Article  CAS  PubMed  Google Scholar 

Chen, T., Wang, M., Chen, Y., Cao, Y. & Liu, Y. Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer. Cell Biosci. 14, 117 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Passaro, A., Brahmer, J., Antonia, S., Mok, T. & Peters, S. Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies. J. Clin. Oncol. 40, 598–610 (2022).

Article  CAS  PubMed  Google Scholar 

Jin, M.-Z. & Jin, W.-L. The updated landscape of tumor microenvironment and drug repurposing. Signal. Transduct. Target. Ther. 5, 166 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Smyth, M. J., Ngiow, S. F., Ribas, A. & Teng, M. W. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat. Rev. Clin. Oncol. 13, 143–158 (2016).

Article  CAS  PubMed  Google Scholar 

Ramachandran, M., Dimberg, A. & Essand, M. The cancer-immunity cycle as rational design for synthetic cancer drugs: novel DC vaccines and CAR T-cells. Semin. Cancer Biol. 45, 23–35 (2017).

Article  CAS  PubMed  Google Scholar 

Li, T. & Qiao, T. Unraveling tumor microenvironment of small-cell lung cancer: implications for immunotherapy. Semin. Cancer Biol. 86, 117–125 (2022).

Article  CAS  PubMed  Google Scholar 

O’Donnell, J. S., Teng, M. W. L. & Smyth, M. J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 16, 151–167 (2019).

Article  PubMed  Google Scholar 

Friedlaender, A. et al. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nat. Rev. Clin. Oncol. 19, 51–69 (2021).

Article  PubMed  Google Scholar 

Pitt, J. M. et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann. Oncol. 27, 1482–1492 (2016).

Article  CAS  PubMed  Google Scholar 

Khanmammadova, N., Islam, S., Sharma, P. & Amit, M. Neuro-immune interactions and immuno-oncology. Trends Cancer 9, 636–649 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mellman, I., Chen, D. S., Powles, T. & Turley, S. J. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity 56, 2188–2205 (2023).

Article  CAS  PubMed  Google Scholar 

Manolakos, P., Boccuto, L. & Ivankovic, D. S. A critical review of the impact of SMARCA4 mutations on survival outcomes in non-small cell lung cancer. J. Pers. Med. 14, 684 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Wang, Y. et al. Mutation of SMARCA4 induces cancer cell-intrinsic defects in the enhancer landscape and resistance to immunotherapy. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-24-2054 (2025).

Article  PubMed  PubMed Central